Rob Koremans, qualified as Medical Doctor from RSM Erasmus University in the Netherlands and Executive MBA in US, has over 30 years’ experience in managerial and executive roles, gained mainly in the pharmaceutical industry at various international companies.
In 1988 he started his professional career at Sanofi in the Netherlands as Product Manager, then being appointed as Head of Cardiovascular Unit.
In 1990, he joined Excerpta Medica Medical Communications, part of Elsevier Group, as International Business Development Director. After one year experience as Marketing & Service Manager at J&J Cilag International in Switzerland, in 1993 he joined Serono Group where he covered different positions with growing responsibilities: he was first General Manager at Ares-Serono in the Netherlands, then Managing Director at Serono Germany and finally Vice President Europe based in Switzerland.
In 2000, he joined Grunenthal as Head of Area Management Europe & USA and Head of Global Marketing, being then appointed Member of the Executive Board.
In 2007, he became Chief Executive Officer and co-owner at Cryo-Save Group, Europe’s leading stem cell storage company; two years later, he was appointed as President and CEO of Zentiva, part of the Sanofi-Aventis Group, in Czech Republic.
In 2012, he joined Teva Pharmaceutical Industries (TPI) as Member of TPI Executive Committee and President & CEO of Teva Pharmaceuticals Europe, then becoming President & CEO Global Specialty Medicines. Finally, in 2018 he joined Nutreco, global leader in animal nutrition, aqua culture and alternative proteins, as Chief Executive Officer.
In December 2021 he joined Recordati as Chief Executive Officer.
Alberto Martinez has a PhD in Pharmacy and an Executive MBA with about twenty years of experience in the pharmaceutical industry.
After the initial activity as Sales Representative and Product Manager at Janssen, in 2003 he joined Mundipharma, where he covered different positions with growing responsibilities both at local and European level: he started his professional path as European Product Manager becoming, in 2006, European Marketing Manager.
One year later he was appointed General Manager at Mundipharma Spain, then widening his responsibilities to Portugal, As of 2014, he was at the same time Managing Director at Napp Pharmaceuticals in UK and Regional Director Northern Europe Mundipharma.
In 2016, he was appointed European Director Commercial Operations and finally, one year later, President and Chief Executive Officer Europe, with global responsibility including R&D, manufacturing and supply chain.
In January 2021 he joined Recordati as Executive Vice President Specialty and Primary Care Business Unit.
Alessandra Abate is a philologist and holds a degree cum laude in Foreign Languages and Literature from La Sapienza University in Rome and an MBA from LUISS University; passionate for transformative leadership and scientific innovation she has a wide experience in change leadership and business model transformation.
Alessandra started her professional career at Merck Sharp & Dohme in Italy in 1999 in Product Management and held commercial roles of increasing responsibility up to the appointment to Marketing Director EMEA & Canada. In 2009 she moved to Switzerland and joined Amgen as Brand Director International, with a mandate to launch the first biologic therapy in Primary Care across all ex-US geographies, and leading a cross-functional team within a joint venture with GSK.
In 2012 she joined Boehringer Ingelheim’s HQ in Germany as Global Head, Planning and Innovation supporting the Chief Marketing Officer and the CEO in the design and roll out of a company-wide integrated business planning process.
In 2014 Alessandra joined the leadership and advisory consulting firm Russell Reynolds Associates in their Amsterdam hub as pharmaceuticals expert and core member of the firm’s healthcare team. She was appointed Managing Director and Global Practice Leader, Biotech & Pharmaceuticals in 2019. After moving to Milan, in 2022, she took over the responsibility of the Italian organization and was appointed Amministratore Delegato.
In March 2024 she joined Recordati as Grup Chief People and Culture Officer.
Gabriele Finzi holds a degree in Business Administration with major in Corporate Finance from the Bocconi University (Milan). After an initial experience in investment banking, he began his corporate career as an M&A Analyst at Barilla, where he took part in a number of deals.
In 2005, he joined Siemens Italy to set up the local M&A department; subsequently he became responsible for the financial planning of the South West Europe region of Siemens Medical Solutions.
In 2008 he joined the Corporate Development department at Recordati where he has been assigned increasing responsibilities and has completed several acquisitions; he was appointed Group Business Development Director in 2012, Vice President Corporate Development in 2016 and Vice President Corporate Development & Licensing in 2019.
Since 2022 he takes the responsibility also for the Innovation activities of the Group, in the role of Executive Vice President Corporate Development, Licensing & Innovation.
Milan Zdravkovic, a Danish national, brings a wealth of experience to his new role, with an impressive track record in developing innovative compounds and leading R&D organizations within the pharmaceutical industry.
His expertise spans a wide range of therapeutic areas, including diabetes, obesity, immunology, hematology, and infectious diseases, and with experience from both rare and non-rare diseases. He has 25 years of life-science experience and has worked at pharma and biotech companies like Novo Nordisk, SOBI-Swedish Orphan Biovitrum and SNIPR Biome, holding increasingly senior roles including Head of R&D and Chief Medical Officer.
Raffaele Sabia holds a degree in Medicine and a post-graduate diploma in Cardiovascular and has a long and rich experience in R&D roles in the pharmaceutical business.
In 1990 he started his professional career at Schwarz Pharma as Medical Adviser for the Cardiovascular area and then became Clinical Research Manager.
In 1997 he moved to AstraZeneca, where he covered different medical roles with growing responsibilities: first he was Senior Clinical Adviser Cardiovascular Area, then Medical Manager Cardiovascular & Metabolic Therapy Areas, later on Medical Affairs Director Primary Care, Neuroscience & Hospital; in 2006 he became, at Headquarters level, European Medical Affairs Director for the Cardiovascular Area.
In the following year, as a part of the same Group, he came back to Italy as Vice President Medical, then Vice President Medical & Regulatory, and finally in 2012 Vice President Medical, Regulatory & Market Access, in charge of the management of Medical Affairs, Clinical Research, Drug Safety, Regulatory Affairs and Market Access Departments.
Finally, in 2013 he joined Novartis Headquarters as Medical Head Region Europe – Cardio Metabolic Franchise, in charge for the entire region of design and implementation of the strategic clinical development and medical affairs programs related to Cardio Metabolic compounds.
During his career he gained a significant experience in different therapeutic areas (Cardiovascular, Metabolic, Gastrointestinal, Respiratory, Neuroscience, Oncology, Anesthesiology, Anti-infective, Vaccines) and contributed to the success of several products.
In July 2017 he joined Recordati S.p.A. as Director of Research and Development.
Alessandro Gilio is a seasoned professional with over 24 years of experience in diverse industrial settings and international environments, having worked in 15 countries across 3 continents. He graduated in Industrial Chemistry from the University of Genoa in Italy and holds an Executive MBA from Hult Ashridge in the UK.
Alessandro began his career at L’Oreal from 2000 to 2005, where he undertook roles in supply chain, quality, and manufacturing. In 2005, he joined McKinsey & Company; as an Associate Partner and member of the European Operations Practice, he supported numerous pharmaceutical clients worldwide and contributed to various operational and strategic projects until 2013. From 2013 to 2019, Alessandro held various leadership positions in operations and strategy at Merck, working across Switzerland and Germany. In 2019, he joined Ferring as Senior Vice President and Head of Global Supply Network Operations. After two years, he assumed the role of Executive Vice President and Head of Global TechOps, gradually expanding his responsibilities to include serving as Chairman of the Board of Ferring India.
In May 2024, Alessandro brought his extensive expertise to Recordati, where he now serves as Executive Vice President of Group Industrial Operations.
Laura Conti is a graduate in foreign languages and literature from Università Cattolica del Sacro Cuore in Milan. She has two post-degree masters, one in business communications and one in journalism.
Laura has more than 20 years of experience in listed companies and international environments and has dealt with almost all aspects of corporate communication, internal and external: from wide-reaching organizational projects to company rebranding and cultural change. She has worked in a range of different industries, including banking, hospitality, digital payments, and e-learning.
Laura joined Recordati in 2022 as Group Internal Communications Director, expanding the role in 2023 and gaining responsibility for external communication. She reports directly to the CEO.
Passionate about humanitarian aid efforts, Laura is also an active volunteer for the Italian Red Cross.
Angelo Siciliano has more than 15 years’ experience across different industrial sectors and geographies.
He joined Recordati in 2015 as Responsible of Corporate Organizational Development, after working in management consulting on various global positions.
He previously held a range of operational roles at Fiat Research Center, Dallara Automobiles, Maserati Racing Team and Italcementi, before moving to Accenture where he developed expertise in running PMI, global transformation and operational excellence programs in Roche, GSK and other multinational companies from non-pharma sectors.
Angelo gained a master’s degree in mechanical engineering with specializations in automotive design and biomechanics and a master in production management at Polytechnic University of Milan.
Since 2014 Angelo is certified master black belt in Lean Manufacturing.
Eugenia Litz joined Recordati as Vice President of Investor Relations in January 2024 and has over 15 years of experience in healthcare investor relations.
Her experience ranges from U.S. small and mid-cap biotech at BioMarin Pharmaceutical and ADC Therapeutics to mid- and large-cap European pharmaceuticals at AstraZeneca and Ipsen. She has worked across a range of therapeutic areas including rare diseases, oncology, respiratory, cardiovascular and neuroscience.
Eugenia started her career as a healthcare equity research analyst at Thomas Weisel Partners and has a BA from Northwestern University in Physiology.
Lucia Abbatantuoni has a degree cum laude in Economics and Management from University of Trento and a Master of Science in Management (with major in Corporate Finance) from Bocconi University.
After gaining experience in consulting, she has spent the last seven years in various strategy and finance roles, ranging from financial planning to Investor Relations in international listed companies such as EssilorLuxottica and Pirelli.
In 2021, she joined Recordati’s Investor Relations department supporting effective investor communication and engagement. From September 2024, she was appointed as Chief of Staff, reporting directly to the CEO, helping to enhance the effectiveness of the Executive Leadership Team (ELT) and serves as a liaison between CEO, ELT, Senior Leaders and external stakeholders. She continues to collaborate closely with Investor Relations.
Stai per lasciare recordati.com per accedere al sito dedicato alle carriere di Recordati
INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003
The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.
In any event we assure you that your data will be processed solely for the above purposes and using the above methods.
The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.
A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).
Requests must be sent to the Data Processor of Recordati:
by email, to the address: ;
or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.
In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.
Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.
